We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+12.02%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$142M
AUM Growth
+$4.53M
Cap. Flow
+$996K
Cap. Flow %
0.7%
Top 10 Hldgs %
70.5%
Holding
62
New
2
Increased
5
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
BDSX icon
Biodesix
BDSX
+$1.08M
2
PRTA icon
Prothena Corp
PRTA
+$518K
3
VTYX
Ventyx Biosciences
VTYX
+$266K
4
SRPT icon
Sarepta Therapeutics
SRPT
+$252K
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$131K

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$602K
2
CGEM icon
Cullinan Oncology
CGEM
+$269K
3
FHTX icon
Foghorn Therapeutics
FHTX
+$257K
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$225K
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40K

Sector Composition

Rank Sector Weight
1 Healthcare 93.28%
2 Energy 4.01%
3 Consumer Staples 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$1.72B
$193K 0.14%
15,000
– –
IFRX icon
52
InflaRx
IFRX
$268M
$185K 0.13%
70,000
– –
CNCE
53
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$134K 0.09%
20,000
– –
ATEC icon
54
Alphatec Holdings
ATEC
$1.27B
$87K 0.06%
+10,000
New +$79.1K
YTEN
55
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$56K 0.04%
781
– –
LSF icon
56
Laird Superfood
LSF
$44.9M
$51K 0.04%
28,000
– –
ELTX icon
57
Elicio Therapeutics
ELTX
$79.8M
$50K 0.04%
5,439
– –
CFRX
58
DELISTED
ContraFect Corporation
CFRX
$34K 0.02%
2,500
– –
SIEN
59
DELISTED
Sientra, Inc.
SIEN
$26K 0.02%
4,000
– –
AWH
60
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$22K 0.02%
4,005
-1,535
-28% -$16.5K
ZNTL icon
61
Zentalis Pharmaceuticals
ZNTL
$357M
– –
-8,000
Closed -$225K
TPTX
62
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-8,000
Closed -$602K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Birchview Capital held 62 positions worth $142M, up 3.3% from $137M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Birchview Capital's Q3 2022 filing shows 2 new, 5 increased, 4 reduced and 2 closed positions. Its largest new stake was Sarepta Therapeutics: 2,500 shares worth $276K. The largest sale was Turning Point Therapeutics, Inc. Common Stock, an estimated $602K.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2022 buy was Sarepta Therapeutics: 2,500 shares worth $276K.
  • Birchview Capital added most to Biodesix in Q3 2022, an estimated $1.08M increase.
  • Birchview Capital's biggest Q3 2022 reduction was Cullinan Oncology, cutting an estimated $269K.
  • Birchview Capital fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $602K.
  • Birchview Capital's ten largest holdings make up 71% of its $142M portfolio in Q3 2022.
  • Birchview Capital opened 2 new positions and closed 2 in Q3 2022.
  • Birchview Capital's portfolio value rose 3.3% quarter-over-quarter to $142M.

Based on Birchview Capital's 13F filing for Q3 2022, filed 7 Nov 2022.